Rezultati pretraživanja
  1. Much needed new guidelines published to help doctors know how long to monitor and patients for post-treatment recurrence. Read the study's recommendations here:

  2. is highly heterogeneous, with various driver mutations. Genetic testing can help identify patients who may benefit from targeted therapy.

  3. prije 9 sati

    Kong et al. find that cell surface molecule promotes PD-L1 expression and establish CD44 as a key positive regulator of PD-L1 expression in and .

  4. prije 13 sati

    Lorlatinib is an important drug for relapsed ALK+ . Am hoping there will be constructive dialogue between NICE and Pfizer to allow an agreement on price.

  5. prije 14 sati

    Do you have lung cancer? Speak to your doctor about what kind of you have and if you could be eligible for the NRG Oncology LU003 trial:

  6. We believe that better health and a brighter future is achieved through collaboration. Hear from Dr. on the importance of teamwork in addressing the needs of people living with ALK+ .

  7. The application, which was based on final progression-free survival findings from the phase III CheckMate-227 trial, was originally filed in 2018 as a first-line treatment for patients with who have tumor mutational burden ≥10 mutations/megabase

  8. 4. velj

    Investigators hope selpercatinib, a highly selective RET inhibitor, will demonstrate potential as a new standard of care for patients with advanced or metastatic treatment-naïve RET fusion–positive in the phase III LIBRETTO-431 trial

  9. 4. velj

    Today is . Our aiForward program helps scientists to harness the power of in pathological and histological image analysis. Learn how Liesbeth Hondelink leverages our aiForward program for non-smell-cell lung cancer research:

  10. 4. velj

    of FDG PET/CT images predicts severe immune-related adverse events in patients with

  11. Therapy for stage IV without driver alterations: and joint guideline update:

  12. 4. velj

    Opening 2020: IMP-MEL a phase 1/2 trial looking at whether a new drug works best alone or in combination in and

  13. 4. velj

    Publication in | Dual disruption of aldehyde dehydrogenases 1 and 3 enhances chemosensitivity in non-small cell lung cancer.

  14. 4. velj

    Bristol-Myers Squibb has withdrawn its application in the European Union for the frontline combination of nivolumab and ipilimumab as a treatment for patients with advanced

  15. 3. velj

    Industry | Bristol-Myers Squibb withdraws European application of Opdivo plus Yervoy for the first-line treatment of advanced non-small cell lung cancer.

  16. 3. velj

    One Year with a Stage IV Lung Cancer diagnosis and going strong. Thank goodness for prayer, positivity, research and amazing medicine. If you have lungs, you can get lung cancer! Love you

  17. 1. velj

    NICE Recommends Against Frontline Osimertinib in EGFR-Mutant

  18. 1. velj

    Despite multiple biomarker-driven advances in Precision Medicine, NSCLC is one of the cancers in which the obstacles in diagnostic testing are severely impeding progress. Here's what we're doing to change that this

  19. 30. sij

    . presents findings from the patient experience study on concurrent chemo-radiation for stage III

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.